Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may reveal which over-80s can survive ICU without losing independence

NCT ID NCT05233267

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether a blood marker called neopterin can predict which patients aged 80 and older will survive an intensive care unit (ICU) stay without losing their ability to perform daily activities. Researchers will measure neopterin levels in blood samples taken within 24 hours of ICU admission and then check patients' independence three months later. The goal is to find a reliable tool to help doctors make difficult decisions about ICU admission for very elderly patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If neopterin proves reliable, it could help doctors decide which elderly patients are most likely to benefit from intensive care, avoiding unnecessary suffering and saving resources.
What could go wrong
This is an observational study, not a treatment trial. Neopterin may not be accurate enough to guide real-world decisions, and results may not apply to all elderly ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

313 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population is selected from 80-year-old patients or more attending intensive care unit for less than 24 hours.

Ages

80 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 80 years old * Admission to intensive care unit before 24 hours * Non opposition expressed by the participant or its relative/trusty person, or emergency inclusion procedure Exclusion Criteria: * Hospitalisation for a scheduled surgery * New admission within a month before previous stay to intensive care unit * Active solid cancer or malignant hemopathy * Immunosuppressant treatment (including corticotherapy \> 5 mg/d) * Autoimmune disease * Tutorship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Elderly patient (80 years old or more) admitted to intensive care are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Elderly patient (80 years old or more) admitted to intensive care

Contacts and locations

Locations

  • Hôpital Saint-Antoine / Service de réanimation

    Paris, 75012, France